International Journal of Oncology

Papers
(The H4-Index of International Journal of Oncology is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Triple‑negative breast cancer therapy: Current and future perspectives (Review)197
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)179
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)100
Cutaneous melanoma and the immunotherapy revolution (Review)71
Serine, glycine and one‑carbon metabolism in cancer (Review)69
A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)65
Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway60
Artificial intelligence radiogenomics for advancing precision and effectiveness in oncologic care (Review)50
Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)50
Current molecular and clinical insights into uveal melanoma (Review)50
High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer48
Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient‑derived organoids43
Update on uveal melanoma: Translational research from biology to clinical practice (Review)35
Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell‑like properties and the epithelial‑mesenchymal transition in oral squamous cell carcinoma cells via the AKT sign34
Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells34
N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer33
Progress and prospects of biomarkers in�primary liver cancer (Review)33
Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-1932
Human‑made electromagnetic fields: Ion forced‑oscillation and voltage‑gated ion channel dysfunction, oxidative stress and DNA damage (Review)32
Curcumin inhibits the cancer‑associated fibroblast‑derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway28
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)27
Riluzole: A neuroprotective drug with potential as a novel anti‑cancer agent (Review)27
‘Reverse Warburg effect’ of cancer‑associated fibroblasts (Review)27
Effects of curcumin complexes on MDA‑MB‑231 breast cancer cell proliferation27
Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review)26
Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma26
Long non‑coding RNA FEZF1‑AS1 facilitates non‑small cell lung cancer progression via the ITGA11/miR‑516b‑5p axis26
0.04981517791748